stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Spectral Medical Inc.

Canada · Market cap: · P/E: · P/S:

Spectral Medical sells a diagnostic test that detects harmful endotoxin in the blood and a blood-filtering device used in hospitals to treat patients with septic shock.

Spectral Medical is a small Canadian company that sells two tightly linked things to hospitals: a test that spots a dangerous toxin in a patient's blood, and a machine that filters that toxin out. Both target sepsis, the body's runaway, life-threatening response to infection, and specifically septic shock, the most severe form.

Spectral Medical Inc. (EDT.TO) Clinical Research Services: line art illustration of two faceless lab technicians in white coats beside a blood sample tube rack and a benchtop lab analyzer machine
Clinical research lab
Spectral Medical earns most of its revenue from its clinical research lab services.

The test is called the Endotoxin Activity Assay. Sepsis is often triggered by endotoxin, a fragment of bacterial cell walls, and the test measures how much of it is in a patient's blood in about half an hour. That matters because doctors treating a crashing patient need to know fast whether endotoxin is the culprit, which tells them whether the filtering treatment makes sense. The treatment is polymyxin B hemoperfusion, sold as Toraymyxin. Blood is pumped out of the patient, run through a cartridge coated with a molecule that grabs endotoxin, and returned to the body. It is used in Japan and parts of Europe; in the United States it is still experimental, and Spectral has spent years trying to win regulatory approval there.


That approval fight is the whole story of the business. The company has burned cash for years and depends on raising money to keep going, which makes it a speculative bet on a single regulatory decision rather than a steady earner. If American regulators clear the device, Spectral would have a new market and a reason for a larger partner to pay up; if not, the company's future gets much harder.

Saved answer · last researched 16 Nov 2026